Eloxx Pharmaceuticals Finalizes 52-Week Phase 2 EXPRESS Study Design in Nonsense-Mutation ADPKD and Appoints T.R. Srinivas, M.D., Chief Medical Officer
US orphan drug designation adds to the European designation, while potential expedited pathways remain dependent on clinical results and FDA discussions.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Eloxx Pharmaceuticals (ELOX) finalized its planned Phase 2 EXPRESS study design for exaluren in nonsense-mutation autosomal dominant polycystic kidney disease (ADPKD). Approximately 60 adults with confirmed PKD1 or PKD2 nonsense mutations will be randomized 1:1 to exaluren or placebo for 52 weeks. The primary endpoint is annualized growth in height-adjusted total kidney volume (htTKV), measured by MRI. Eloxx expects first dosing in 3Q 2027 and topline results in 1H 2029.
FDA feedback identified a substantial, durable htTKV effect with supporting kidney-function and safety data as a potential basis for Breakthrough Therapy Designation. Expedited pathways depend on results and further FDA discussions. Exaluren received US orphan drug designation for ADPKD, adding to Europe. Eloxx appointed T.R. Srinivas as chief medical officer. Peer-reviewed preclinical data showed restoration of full-length polycystin-1 in cells carrying PKD1 nonsense mutations.
How this balance works
Rhea-AI gives every point it takes from this document a weight. Minor counts 1, Moderate 3 and Major 9, so one Major point outweighs several Minor ones. The bar adds up the weights on each side, and when neither side holds more than 65% of the total the balance reads Mixed.
It reads the document as published, with the same rules for every company, and it does not look at what the market expected or at how the stock traded, so a point can be objectively good on a day the stock falls.
Rhea-AI Sentiment measures something else, the tone of the wording.
Hollow bars mark forward-looking points. How the balance works
Positive
- Moderate pointEXPRESS design finalized: approximately 60 adults randomized 1:1 to exaluren or placebo for 52 weeks.
- Moderate pointFDA feedback identified substantial, durable htTKV effects with supporting kidney-function and safety data as a potential Breakthrough designation basis.
- Minor point. Forward-looking: it has not happened yet and may not happen.First dosing expected in 3Q 2027, with 52-week topline results expected in 1H 2029.
- Minor pointUS orphan drug designation granted for exaluren in ADPKD, adding to the European designation.
- Minor pointhtTKV change is identified by FDA as a potential surrogate endpoint for accelerated approval in ADPKD.
- Minor pointPeer-reviewed preclinical data showed full-length polycystin-1 restoration in PKD1 nonsense-mutation cells and reduced cyst-promoting signaling.
Negative
- Minor point. Forward-looking: it has not happened yet and may not happen.Expedited pathways or potential designation depend on clinical results and further FDA discussions.
Details
Market move: ELOX +6.40% vs previous close. Phase 2 study design
On Oct 20, the day this news came out, the latest delayed price for ELOX is 6.40% above the previous close. Our momentum scanner has recorded 2 alerts for this stock so far that day. The latest delayed price is $13.30.
Data tracked by StockTitan Argus (15 min delayed). Upgrade to Gold for real-time data.
Key Figures
- Planned enrollment
- approximately 60 adults
- EXPRESS Phase 2 study
- Randomization ratio
- 1:1
- Exaluren versus placebo
- Dosing duration
- 52 weeks
- EXPRESS Phase 2 study
- First patient dosing
- 3Q 2027
- Expected
- Topline results
- 1H 2029
- Expected after 52 weeks of study
Key Terms
adpkd medical
breakthrough therapy designation regulatory
surrogate endpoint regulatory
orphan drug designations regulatory
AI-generated analysis. How Rhea-AI works. Not financial advice.
- EXPRESS Phase 2 design finalized: 52 weeks of dosing of approximately 60 patients randomized 1:1 to exaluren or placebo, with annualized htTKV growth as the primary endpoint
- Substantial, durable htTKV effect could support Breakthrough Therapy Designation; FDA also lists htTKV as a potential surrogate endpoint for accelerated approval in ADPKD
- First patient dosing expected in 3Q 2027, and 52-week topline data expected in 1H 2029
- Orphan drug designation granted for ADPKD in the US in addition to
Europe - T.R. Srinivas, M.D., joins from Novartis as Senior Vice President and Chief Medical Officer, strengthening medical leadership across Eloxx's ADPKD and Alport programs
- Peer-reviewed preclinical data show exaluren restores full-length polycystin-1 in cells carrying PKD1 nonsense mutations and partially corrects disease-associated signaling pathways
EXPRESS Phase 2 Design Finalized
Following significant interactions between regulatory authorities and key opinion leaders, Eloxx has now finalized the design of its planned global ADPKD clinical trial. EXPRESS, a global Phase 2 clinical trial, is designed to enroll 60 adults with genetically confirmed PKD1 or PKD2 nonsense mutations, randomized 1:1 to receive exaluren or placebo for 52 weeks. The primary efficacy endpoint is the annualized rate of change in height-adjusted total kidney volume (htTKV), assessed by MRI at baseline and Weeks 28, 36 and 52. The design is intended to better characterize treatment effects over time and generate a full year of kidney-function and safety data. First patient dosing is expected in 3Q 2027, with 52-week topline results expected in 1H 2029.
In written pre-IND feedback, FDA feedback noted that a substantial and durable height-adjusted Total Kidney Volume (htTKV) treatment effect, with supporting eGFR and safety data could serve as a potential basis for Breakthrough Therapy Designation. Separately, FDA identifies change in htTKV as a potential surrogate endpoint for accelerated approval in ADPKD. Any expedited pathway or potential designation would depend on clinical results and further FDA discussions.
Exaluren has also now received orphan drug designations for ADPKD in
"We have deliberately designed EXPRESS as a 52-week study to generate a more robust assessment of htTKV growth change and a full year of kidney-function and safety data. We believe this trial design brings considerable potential regulatory and value creation opportunities," said Sumit Aggarwal, President and Chief Executive Officer of Eloxx. We have also strengthened our clinical team, including the appointment of Dr. T.R. Srinivas as Chief Medical Officer, to advance our rare kidney programs and support the EXPRESS and EXACT clinical studies."
Peer-reviewed preclinical data show exaluren restores full-length polycystin-1 in cells carrying PKD1 and PKD2 nonsense mutations, with readthrough accompanied by reduced signaling through cyst-promoting pathways.
Appointment of T.R. Srinivas, M.D. as SVP, Chief Medical Officer
Eloxx also announced the appointment of T.R. Srinivas, M.D., as Senior Vice President and Chief Medical Officer. Dr. Srinivas will provide renal medical leadership across the Company's Alport and ADPKD programs, including medical strategy, interpretation of clinical evidence and investigator engagement. Dr. Srinivas brings extensive experience in nephrology, clinical research and medical leadership. At Novartis, his responsibilities included
"People with ADPKD caused by a nonsense mutation tend to reach kidney failure earlier, and no available therapy addresses the genetic mutation driving their disease," said Dr. Srinivas. "Exaluren is designed to restore the missing protein itself, which is a fundamentally different approach. I am excited to join Eloxx at this stage and to help bring this novel potential therapy to patients."
Prior to joining Novartis, Dr. Srinivas served as Chief Medical Officer at CareDx and Chief of the Division of Nephrology and Hypertension at University Hospitals in
About Nonsense Mutation ADPKD
Autosomal dominant polycystic kidney disease is the most common inherited kidney disease, affecting an estimated 160,000 to 200,000 people in
About Exaluren
Exaluren is Eloxx's investigational, small-molecule ribosomal modulator designed to promote readthrough of premature stop codons caused by nonsense mutations, enabling production of full-length, functional protein. Exaluren is being developed for rare kidney diseases caused by nonsense mutations, including nonsense mutation Alport syndrome and nonsense mutation autosomal dominant polycystic kidney disease (ADPKD). The FDA and the European Commission have each granted orphan drug designations to exaluren for the treatment of Alport syndrome and ADPKD.
About Eloxx Pharmaceuticals
Eloxx Pharmaceuticals, Inc. (Nasdaq: ELOX) is a clinical-stage biopharmaceutical company developing novel, small-molecule product candidates designed to modulate the ribosome and promote readthrough of premature stop codons induced by nonsense mutations to enable the production of full-length proteins. Eloxx's lead product candidate, exaluren, is being developed for the treatment of rare kidney diseases, including nonsense mutation Alport syndrome and nonsense mutation autosomal dominant polycystic kidney disease (ADPKD). Eloxx has also exclusively licensed its product candidate, ZKN-013, to Almirall, S.A., which is developing it for the treatment of rare dermatological diseases associated with nonsense mutations.
For more information, please visit www.eloxxpharma.com.
Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements other than statements of present and historical facts contained in this press release, including without limitation statements regarding the expected timing of the initiation of, and results from, clinical trials of the Company's product candidates, including the Phase 2b clinical trial of exaluren in nonsense mutation Alport syndrome and the EXPRESS Phase 2 clinical trial of exaluren in nonsense mutation ADPKD; the design of the EXPRESS trial and the potential for exaluren to receive Breakthrough Therapy designation or pursue accelerated approval; the anticipated contributions of the Company's Chief Medical Officer; the potential benefits of orphan drug designation; the Company's collaboration with Almirall and the potential to receive milestone and royalty payments; and the potential of the Company's product candidates to treat nonsense mutations, are forward-looking statements. Forward-looking statements can be identified by words such as "aim," "may," "will," "expect," "plan," "anticipate," "could," "intend," "target," "project," "believe," "estimate," "potential," "seeks," or "continue," or the negative of these terms or other similar expressions, although not all forward-looking statements contain these words. Forward-looking statements are based on management's current plans, estimates, assumptions and projections, and are subject to known and unknown risks, uncertainties and assumptions, and actual results may differ materially from those expressed or implied due to various important factors, including, but not limited to, the Company's need for and ability to obtain additional capital; the uncertainty and expense of clinical development; the fact that results from preclinical studies and early clinical trials are not necessarily predictive of future results; and other important factors discussed under the caption "Risk Factors" and elsewhere in the Company's Quarterly Report on Form 10-Q for the quarterly period ended June 30, 2026 and its other filings with the SEC, accessible on the SEC's website at www.sec.gov and on the "Financials & Filings" page of the Company's website. All forward-looking statements speak only as of the date of this press release and, except as required by applicable law, the Company undertakes no obligation to update or revise any forward-looking statements contained herein.
Contact
Investor Relations
Eloxx Pharmaceuticals, Inc.
ir@eloxxpharma.com
(781) 577-5300
View original content to download multimedia:https://www.prnewswire.com/news-releases/eloxx-pharmaceuticals-finalizes-52-week-phase-2-express-study-design-in-nonsense-mutation-adpkd-and-appoints-tr-srinivas-md-chief-medical-officer-302914139.html
SOURCE Eloxx Pharmaceuticals, Inc.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What is the design of Eloxx's Phase 2 EXPRESS trial?
EXPRESS plans to randomize approximately 60 adults with genetically confirmed PKD1 or PKD2 nonsense mutations 1:1 to exaluren or placebo for 52 weeks. The primary efficacy endpoint is the annualized rate of change in height-adjusted total kidney volume, a kidney-size measure adjusted for height.
When does Eloxx expect EXPRESS dosing and results?
Eloxx expects first patient dosing in 3Q 2027 and 52-week topline results in 1H 2029.
How will Eloxx measure kidney volume during EXPRESS?
EXPRESS will assess height-adjusted total kidney volume by MRI at baseline and Weeks 28, 36 and 52. Eloxx designed the study to characterize treatment effects over time and generate a full year of kidney-function and safety data.